Why ImageneBio, Inc.’s (IMA) Stock Is Down 5.41%
As of Friday, July 31, ImageneBio, Inc.’s IMA share price has dipped by 5.41%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Commentary & Analysis
Why ImageneBio, Inc.’s (IMA) Stock Is Down 5.53%
As of Thursday, July 23, ImageneBio, Inc.’s IMA share price has dipped by 5.53%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why ImageneBio, Inc.’s (IMA) Stock Is Up 5.86%
As of Monday, July 20, ImageneBio, Inc.’s IMA share price has surged by 5.86%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why ImageneBio, Inc.’s (IMA) Stock Is Down 7.32%
As of Thursday, July 16, ImageneBio, Inc.’s IMA share price has dipped by 7.32%, which has investors questioning if this is right time to buy.Michael Rose
Why ImageneBio, Inc.’s (IMA) Stock Is Down 5.83%
As of Wednesday, July 08, ImageneBio, Inc.’s IMA share price has dipped by 5.83%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | IMA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $62.5 | $579.1 | 18% |
|
| Shares Out (Mil) | 11.2 | 43.0 | 22% |
|
| Institutional Ownership | 87.1% | 84.3% | 55% |
|
| Float (Mil) | 5.6 | 46.8 | 13% |
|
| Beta | na | 0.62 | na |
|
| Avg Daily Volume (000s) | 10 | 285 | 16% |
|
| Price Change (52-week) |
(63.8%) | 63.8% | 11% |
|
| Growth | IMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($1.105) | ($4.480) | ($3.980) | |
| Month Ago EPS | ($1.105) | ($4.480) | ($3.980) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.990) | ($3.855) | ($3.365) | |
| Year/Year Chg | 16.7% | (53.6%) | (43.3%) | |
| Financials | IMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | ($50) | ($11) | 16% |
|
| EPS (TTM) | ($7.059) | ($0.500) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($55) | ($6) | 9% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 10% |
|
| Enterprise Value (Q1) (Mil) | ($49) | $522 | 1% |
|
| Valuation | IMA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.51 | 2.73 | 9% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | IMA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (66.8%) | (24.6%) | 9% |
|
| ROE | 152.9% | (19.7%) | 97% |
|
| Liabilities to Assets | 9.8% | 35.5% | 5% |
|
| F-Score | 1 | 3 | na |
|
ImageneBio, Inc. did not pass any screens on 7/31/2026.
